What Is Betacellulin? Definition and What Research Reports

Betacellulin (BTC) is a protein growth factor belonging to the epidermal growth factor (EGF) family. Like other members of that family, it is produced as a transmembrane precursor protein that is enzymatically cleaved to release a soluble, mature form, and it exerts its effects by binding receptors of the ErbB (EGF receptor) family. Its name comes from its original source: it was identified in material derived from pancreatic beta-cell tumour cells, and much of the subsequent literature has examined it in the context of pancreatic islets. In research writing, "betacellulin" and the abbreviation "BTC" are used interchangeably, and the human gene is written BTC.

This page is for educational purposes only and is not medical advice; consult a licensed physician about any health question or any compound discussed in the scientific literature.

What class of molecule is betacellulin?

Betacellulin is classified as a growth factor rather than a hormone or a short synthetic peptide. It is considerably larger than the research peptides that glossaries often cover: it is a glycosylated protein containing the six-cysteine "EGF motif" that defines the EGF ligand family, and that motif forms the disulfide-bonded loop structure required for receptor binding. A structure–function review described betacellulin as an EGF-family ligand produced as a membrane-anchored precursor that is processed to a soluble mature form (PMID 10940639). A later review of its structural properties and biological roles likewise characterised betacellulin as an ErbB-family ligand with features that distinguish it from EGF and transforming growth factor alpha (PMID 24440602).

Receptor signalling

What sets betacellulin apart within the EGF family is its receptor range. Reviews of its biology reported that betacellulin binds more than one ErbB receptor and can engage receptor heterodimers, giving it a broader signalling profile than ligands that bind only the classical EGF receptor (PMID 10940639, PMID 24440602). In pancreatic islet work, researchers reported that betacellulin-induced alpha-cell proliferation was mediated by ErbB3 and ErbB4 (PMID 33553143). This multi-receptor behaviour is one reason the molecule appears in literature on development, metabolism and oncology alike.

Where the term comes from

The name is a compound of "beta" (from the insulin-producing beta cells of the pancreatic islet) and "cellulin". Betacellulin was first recovered from pancreatic beta-cell tumour material, and early characterisation work framed it as a mitogen with activity on several cell types beyond its tissue of origin (PMID 10940639). Later reviews retained that framing while adding structural detail and a wider survey of tissues in which the protein is expressed (PMID 24440602).

How the term is used in peptide and growth-factor research

In the research literature, "betacellulin" generally appears in one of four contexts:

• As a ligand — a tool used in cell-culture experiments to activate ErbB receptors and compare signalling outputs with other EGF-family ligands.
• As an endogenous signal — a protein whose expression levels in a tissue are measured and correlated with a biological state, such as islet cell turnover or liver injury.
• As a candidate node in disease networks — identified through omics or network analysis as a molecule whose abundance tracks with a disease process.
• As a target — a molecule whose blockade or reduction is tested in preclinical cancer or metabolic models.

It is worth noting that betacellulin is a naturally occurring signalling protein studied in laboratory and animal systems. The verified literature summarised here consists of reviews and preclinical investigations; none of the papers cited on this page described an approved betacellulin medicine or a human dosing protocol.

What the published literature reports

Pancreatic islet cells

The islet remains betacellulin's best-studied setting. In a 2020 study in Frontiers in Cell and Developmental Biology, researchers reported that betacellulin induced alpha-cell proliferation, that this effect was mediated by the receptors ErbB3 and ErbB4, and that the process may contribute to beta-cell regeneration (PMID 33553143). Earlier reviews had already positioned betacellulin as a factor of interest in pancreatic biology on the basis of its origin and its activity on islet-derived cells (PMID 10940639, PMID 24440602).

Liver and metabolic disease models

A 2023 report in EMBO Molecular Medicine used multi-omic network analysis and identified betacellulin as a novel target of omega-3 fatty acid attenuation of western diet-induced nonalcoholic steatohepatitis (PMID 37859621). In that framing, betacellulin was not administered as a therapy; the study treated it as a node within a diet-driven disease network whose behaviour changed alongside the dietary intervention.

Glioblastoma

In 2020, a paper in Neuro-Oncology reported that betacellulin drove therapy resistance in glioblastoma (PMID 31678994). That finding is a reminder that a growth factor's biology is context-dependent: the same receptor-activating capacity that features in regenerative research also appears in work describing tumour behaviour.

Summary table of the cited literature

Betacellulin Research: What Studies Report

None of the verified papers summarised on this page reported human dosing, human safety monitoring or adverse-event tables for administered betacellulin, so no safety profile can be described from them. What the literature does contain is a signal about biological context: researchers reported that betacellulin drove therapy resistance in glioblastoma, which situates the molecule within tumour biology as well as regenerative biology (PMID 31678994). Reviews of its structure and roles similarly described a ligand with broad receptor engagement across multiple tissues rather than a narrowly targeted factor (PMID 24440602). Readers comparing sources should note the difference between a review that catalogues reported biology and an experimental paper that tests a single intervention in a single model.

What the cited literature does not establish

• No human efficacy data. The verified papers are reviews and preclinical studies; none described controlled human trials of betacellulin.
• No dosing information. Because no human administration study appears in the verified set, no doses, schedules or durations are stated on this page.
• No cross-disease generalisation. A finding in glioblastoma models (PMID 31678994) does not transfer to islet biology (PMID 33553143), and vice versa.

Related terms

• EGF family — the ligand group that includes epidermal growth factor, transforming growth factor alpha, heparin-binding EGF-like growth factor and betacellulin (PMID 10940639).
• ErbB receptors — the receptor tyrosine kinase family through which betacellulin signals, including ErbB3 and ErbB4 in islet work (PMID 33553143).
• Ectodomain shedding — the cleavage process that releases the soluble mature protein from its membrane-bound precursor, described in reviews of betacellulin structure (PMID 24440602).

References

• Structure-function and biological role of betacellulin (The International Journal of Biochemistry & Cell Biology, 2000)
• The ABC of BTC: structural properties and biological roles of betacellulin (Seminars in Cell & Developmental Biology, 2014)
• Betacellulin drives therapy resistance in glioblastoma (Neuro-Oncology, 2020)
• Betacellulin-Induced α-Cell Proliferation Is Mediated by ErbB3 and ErbB4, and May Contribute to β-Cell Regeneration (Frontiers in Cell and Developmental Biology, 2020)
• Multi-omic network analysis identified betacellulin as a novel target of omega-3 fatty acid attenuation of western diet-induced nonalcoholic steatohepatitis (EMBO Molecular Medicine, 2023)